Skip to main content

Dipeptidyl peptidase-4 inhibitors


04-17-2018 | Medications | News

Modern antidiabetic medications ranked for survival benefits

A network meta-analysis published in JAMA offers indirect comparisons of the survival benefits associated with use of the most recent antidiabetic agents.

04-03-2018 | Alogliptin | Highlight | News

Support for alogliptin as add-on therapy for type 2 diabetes

Adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin and sulfonylurea treatment may improve glycemic control in patients with type 2 diabetes and high cardiovascular risk, a post-hoc analysis of the EXAMINE trial suggests.

03-21-2018 | Dipeptidyl peptidase-4 inhibitors | Highlight | News

DPP-4 inhibitor use linked to inflammatory bowel disease risk

Researchers have detected a possible increased risk for inflammatory bowel disease among users of dipeptidyl peptidase-4 inhibitors.

Read more

Related topics





01-13-2017 | Cardiovascular outcomes | Editorial | Article

Clinical implications of cardiovascular outcomes trials in type 2 diabetes

What do the results of CVOTs mean for practicing clinicians? Medicine Matters contributor, Carol Wysham reviews the latest evidence and guidelines for reducing CV risk in patients with type 2 diabetes.

In depth

01-15-2018 | Type 1 diabetes | Hot topic review | Article

What do we know about adjunct non-insulin medications in type 1 diabetes?

medwireNews outlines which medications have so far been tested as adjunct treatments for type 1 diabetes and summarizes the key trial data showing their benefits or otherwise.

Journal articles and book chapters

05-04-2018 | Sodium-glucose cotransporter-2 inhibitors | Review | Article

Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes

A systematic review and meta-analysis

Zheng et al. JAMA 2018; 319:1580. doi: 10.1001/jama.2018.3024

04-28-2018 | Heart failure | Review | Article

SGLT2 inhibition and heart failure: Current concepts

Custodio JS et al. Heart Fail Rev 2018; 23: 409–418. doi: 10.1007/s10741-018-9703-2

04-18-2018 | Linagliptin | Review | Article

The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes: Focus on linagliptin

Aroor AR, Manrique-Acevedo C, DeMarco VG. Cardiovasc Diabetol 2018; 17: 59. doi: 10.1186/s12933-018-0704-1

Case reports

image credits